Guixiang Tai

1.1k citations
52 papers · 949 indexed · h-index 21

Guixiang Tai

52 papers receiving 943 citations

Peers

Guixiang Tai
Comparison fields: 5 of 96
  • Immunology 427
  • Cancer Research 163
  • Molecular Biology 476
  • Oncology 166
  • Immunology and Allergy 26
Replace Haifeng Song with:
Haifeng Song China
Xueqiang Zhao China
Arnold I. Chin United States
Vera M. Ruda United States
Ahmad Hosseini Iran
Svetlana Hamm Germany
Satoshi Takaki Japan
Karen Bräutigam Germany
Pilar Lasierra Spain
Guixiang Tai relative to Haifeng Song China Haifeng Song's profile →
Citations per field
00.5×2.8×
Haifeng Song · 1×
Citations per year

Countries citing papers authored by Guixiang Tai

Since Specialization
Citations

This map shows the geographic impact of Guixiang Tai's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Guixiang Tai with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Guixiang Tai more than expected).

Fields of papers citing papers by Guixiang Tai

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Guixiang Tai. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Guixiang Tai. The network helps show where Guixiang Tai may publish in the future.

Co-authorship network

The 25 scholars most cited alongside Guixiang Tai, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Guixiang Tai Line = papers co-authored together Guixiang Tai links everyone, so they are left out of the graph.

All Works

20 of 20 papers shown
#Work
1 20242
2 20232
3 20222
4 20219
5 20183
6 201639
7 20163
8 20169
9 201511
10 201534
11 201421
12 201428
13 201432
14
Establishment of indirect sandwich ELISA method for serum MUC1 detection and its application in diagnosis of lung cancer
20131
15
Effect of Escherichia coli maltose-binding protein on mouse Th1 cell activation.
20098
16 200928
17 200910
18 200935
19 200840
20 200853

About Guixiang Tai

Guixiang Tai is a scholar working on Immunology, Cancer Research and Microbiology, having authored 52 papers that have together received 949 indexed citations. Recurring topics across this work include Glycosylation and Glycoproteins Research (15 papers), Immunotherapy and Immune Responses (13 papers), Immune Response and Inflammation (13 papers), TGF-β signaling in diseases (9 papers), Monoclonal and Polyclonal Antibodies Research (7 papers), Immune cells in cancer (7 papers), vaccines and immunoinformatics approaches (6 papers) and NF-κB Signaling Pathways (6 papers). The work is most often cited by research in Immunology (427 citations), Cancer Research (163 citations) and Molecular Biology (476 citations). Guixiang Tai has collaborated with scholars based in China, Japan and Canada. Frequent co-authors include Weihua Ni, Juan Wang, Hongyan Yuan, Zhonghui Liu, Fei Xie, Ruiping Zhai, Fangfang Chen, Jingyan Ge, Mitsufumi Mayumi and Yue Lan. Their work appears in journals such as The Journal of Immunology, International Journal of Molecular Sciences and The International Journal of Biochemistry & Cell Biology.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026